SARS-CoV-2 reoviral vector-based vaccine (Virocure)

N/A

Report date: 2025/01/26 16:18:18

Base Information

Drug NameSARS-CoV-2 reoviral vector-based vaccine (Virocure)
Drug Alias NameCOVID-19 vaccine (Virocure)
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaSouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVirocure LLC
China Registration ClassN/A

Develop Information

Active CompaniesGenvira Biosciences IncUniversity Of OttawaVirocure LLC
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A